Senior Director, Brand Experience & Engagement

Zenas is a clinical-stage global biopharmaceutical company committed to becoming a leader in the development and commercialization of transformative therapies for patients with autoimmune diseases. Our core business strategy combines our experienced leadership team with a disciplined product candidate acquisition approach to identify, acquire and develop product candidates globally that we believe can provide superior clinical benefits to patients living with autoimmune diseases.

Zenas is advancing two late-stage, potential franchise molecules, obexelimab and orelabrutinib. Obexelimab, Zenas’ lead product candidate, is a bifunctional monoclonal antibody designed to bind both CD19 and FcγRIIb, which are broadly present across B cell lineage, to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them. We believe that obexelimab’s unique mechanism of action and self-administered, subcutaneous injection regimen may broadly and effectively address the pathogenic role of B cell lineage in chronic autoimmune disease.

Orelabrutinib is a potentially best-in-class, highly selective CNS-penetrant, oral, small molecule Bruton’s Tyrosine Kinase (BTK) inhibitor with the potential to address compartmentalized inflammation and disease progression in Multiple Sclerosis (MS). Zenas’ earlier stage programs include ZB021, a clinical-stage, potentially best-in-class, oral, IL-17AA/AF inhibitor; ZB022, a preclinical, potentially best-in-class, oral, brain-penetrant, TYK2 inhibitor; and ZB014, a preclinical half-life extended anti-CD-19 and FcγRIIb monoclonal antibody.

We are seeking top talent who share our commitment to patients and have a track record of success in acquiring, developing and commercializing products across the globe. Our colleagues have an opportunity to engage in a fast-paced learning environment and experience individual and organizational success as we work towards becoming a global immunology and autoimmune disease leader, while living our values of Transparency, Relationships, Urgency, Excellence and Innovation –
TRUE Innovation
!

Zenas is seeking a strategic, digitally fluent marketer and commercial leader to help shape the obexelimab brand strategy and how it comes to life in market — leading the brand and go-to-market experience for the asset’s first anticipated launch in IgG4-Related Disease and building scalable solutions for future launches.

Reporting to the SVP, Commercial Strategy & Corporate Affairs, this leader will partner closely with the Brand Director to translate obexelimab’s brand strategy into a connected brand experience across digital, content, CRM, disease awareness, patient/caregiver education, congress extensions, and other customer engagement channels. Partnering closely with the Senior Brand Director, they contribute to brand positioning and own its expression as a consistent, compelling experience across every audience segment, channel, and touchpoint.

This leader brings a modern approach to commercialization — connecting marketing, field, digital, and patient services into one commercial engine. The payoff: a scalable, externally visible brand presence that lets lean teams launch with the impact of a far larger organization.

• Leads the go-to-market engagement strategy and brand experience activation for obexelimab in partnership with the Brand Director, defining how the brand reaches and engages each audience across marketing, field, digital, and patient services as one connected commercial system.
• Designs the customer engagement model and journey architecture, sequencing how and when the brand shows up from pre-launch market development through commercialization.
• Co-develops brand positioning with the Senior Brand Director, and owns its expression as a consistent, compelling experience across every channel and touchpoint.
• Aligns field, marketing, and patient-services engagement into a single orchestrated plan, eliminating the disconnects that fragment the customer experience.

• Contributes to the obexelimab commercial strategy as a member of the…